McKinsey & Company

Company

Related News

Late-Stage CNS and Oncology Assets Draw Biotech M&A Interest

May 14, 2026

Biotech M&A is shifting toward late-stage CNS and oncology assets with human clinical validation. Oncotelic Therapeutics said it advanced global IP protection for OT-101 and CNS drug delivery.

Late-Stage CNS and Oncology Assets Drive Biotech M&A Strategy Shift

Feb 17, 2026

Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation over early-stage programs. Oncology and CNS programs have emerged as strategic M&A targets due to large commercial markets and significant unmet medical needs.